The evaluation of clinical features of chronic lymphocytic leukemia patients followed up at Trakya University Medical Faculty

Basit Öğe Kaydı
dc.authorscopusid35546856700
dc.authorscopusid23060179500
dc.authorscopusid6701664192
dc.authorscopusid15758644000
dc.authorscopusid15756259700
dc.authorscopusid7004457653
dc.authorscopusid7003486028
dc.contributor.authorPamuk G.E.
dc.contributor.authorDönmez S.
dc.contributor.authorTurgut B.
dc.contributor.authorYeşil N.
dc.contributor.authorTekgündüz E.
dc.contributor.authorDemir M.
dc.contributor.authorVural Ö.
dc.date.accessioned2024-06-12T10:28:36Z
dc.date.available2024-06-12T10:28:36Z
dc.date.issued2006
dc.description.abstractObjective: To determine the general clinical features, treatment modalities and response to therapy, survival and the importance of prognostic factors that might influence survival in chronic lymphocytic leukemia (CLL) patients diagnosed at our center. Material and Methods: We evaluated 65 CLL patients (39 males, 26 females, median age: 64) followed up at Trakya University Medical Faculty, Department of Internal Medicine, Division of Hematology between 1998 and 2005. Rai staging system was used for clinical staging. Results: At initial diagnosis, 4 cases (6.2%) had stage 0, 14 (21.5%) stage I, 20 (30.8%) stage II, 10 (15.4%) stage III, and 17 (26.2%) stage IV disease. Five patients (7.9%) were asymptomatic at initial presentation. According to Rai stages, 4 were early-stage (Rai 0, I, II) and 3 were advanced-stage (Rai III, IV) patients. Autoimmune hemolytic anemia was detected in 7 (10.8%) and secondary malignancy in 6 (9.2%) CLL patients. When CLL was diagnosed, 23 early Rai stage patients (60.5%) and 22 (80.5%) late Rai stage patients were treated. Best response to first-line therapy (55.6%) was achieved with chlorambucil. The median survival of subjects with early-stage disease at initial diagnosis was 130 months, and that of advanced-stage subjects was 118 months (p= 0.04). Five- and 10-year survival rate was 77% and 49% respectively. Cox multivariable regression analysis showed that having advanced-stage disease at diagnosis (OR: 4.2, p= 0.01) and age >60 years (OR: 5.6, p= 0.036) were independently poor prognostic parameters. Conclusion: The results of this study suggest that advanced-stage disease and age >60 years at initial diagnosis are poor prognostic parameters in CLL patients. Copyright © 2006 by Türkiye Klinikleri.en_US
dc.identifier.endpage616en_US
dc.identifier.issn1300-0292
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-33845986727en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage611en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/17331
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofTurkiye Klinikleri Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectB-Cell; Chlorambucil; Chronic; Leukemia; Lymphocytosisen_US
dc.subjectChlorambucil; Fludarabine; Adult; Article; Autoimmune Hemolytic Anemia; Cancer Patient; Cancer Staging; Cancer Survival; Cancer Therapy; Chronic Lymphatic Leukemia; Clinical Evaluation; Clinical Feature; Controlled Study; Female; Follow Up; Human; Major Clinical Study; Male; Metastasis; Prognosis; Proportional Hazards Model; University Hospitalen_US
dc.titleThe evaluation of clinical features of chronic lymphocytic leukemia patients followed up at Trakya University Medical Facultyen_US
dc.title.alternativeTrakya ÜNiversitesi Tip Fakültesi'nde takip edilen kronik lenfositik lösemi olgularinin klinik özelliklerinin de?erlendirilmesien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu